A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease
3 other identifiers
interventional
500
14 countries
154
Brief Summary
This is a Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of KarXT in male and female subjects who are aged 55 to 90 years and have mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD. The primary objective of the study is to evaluate the efficacy of KarXT compared with placebo in the treatment of subjects with psychosis associated with AD as measured by the Neuropsychiatric Inventory-Clinician (NPI-C): Hallucinations and Delusions (H+D) score.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3
Started Aug 2023
Typical duration for phase_3
154 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 28, 2023
CompletedFirst Submitted
Initial submission to the registry
November 3, 2023
CompletedFirst Posted
Study publicly available on registry
November 13, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 9, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 9, 2026
April 30, 2026
April 1, 2026
3.3 years
November 3, 2023
April 29, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Change from Baseline to End of Treatment in the Neuropsychiatric Inventory-Clinician: Hallucinations and Delusions (NPI-C: H+D) score
Neuropsychiatric Inventory-Clinician: Hallucinations and Delusions scale includes 2 domains from the NPI-C scale, namely, hallucinations and delusions. These 2 domains include the following number of items to be rated by the clinician: Hallucinations, 7 items (maximum score = 21) and Delusions, 8 items (maximum score = 24). The maximum score for the NPI-C: H+D scale is 45. Higher scores on this scale indicate worse outcomes.
Baseline and end of Treatment (up to 14 Weeks)
Secondary Outcomes (5)
Change from Baseline to End of Treatment in the Clinical Global Impressions-Severity (CGI-S) scale
Baseline and end of Treatment (up to 14 Weeks)
Change From Baseline to end of Treatment in NPI-C Core score: Hallucinations, Delusions, Agitation, and Aggression Domains
Baseline and end of Treatment (up to 14 Weeks)
Change From Baseline to end of Treatment in NPI-C: Agitation score
Baseline and end of Treatment (up to 14 Weeks)
Change From Baseline to end of Treatment in NPI-C Core score: Caregiver Distress scale (Hallucinations, Delusions, Agitation, and Aggression domains)
Baseline and end of Treatment (up to 14 Weeks)
Responder Rate
Baseline and end of Treatment (up to 14 Weeks)
Study Arms (2)
KarXT
EXPERIMENTALXanomeline and Trospium Chloride Capsules
Placebo
PLACEBO COMPARATORPlacebo capsules
Interventions
Eligibility Criteria
You may qualify if:
- Is a male or female aged 55 to 90 years, inclusive, at Screening.
- Can understand the nature of the trial and protocol requirements and provide informed consent or assent before any study assessments are performed.
- Meets clinical criteria for Possible AD or Probable AD.
- Must have a magnetic resonance imaging (MRI) or computed tomography (CT) scan of the brain (completed within the past 5 years) taken during or subsequent to the onset of dementia to rule out other central nervous system (CNS) disease that could account for the dementia syndrome, e.g., major stroke, neoplasm, subdural hematoma. If not available, a non-contrast brain MRI or non-contrast head CT must be done during Screening.
- Living at the same home or residential assisted-living facility for a minimum of 6 weeks before Screening.
- Have an identified study partner who should have daily contact (approximately 10 hours a week or more).
- History of psychotic symptoms (meeting International Psychogeriatric Association criteria) (Cummings 2020) for at least 2 months prior to Screening.
- CGI-S scale with a score ≥ 4 at Screening and Baseline.
- AD subjects are required to have NPI-C: Hallucinations and Delusions (H+D) score of ≥ 6 AND meet at least 1 of the following criteria at Screening and Baseline:
- Moderate to severe delusions, defined as NPI-C: Delusions domain score of ≥ 2 on 2 of the 8 items OR
- Moderate to severe hallucinations, defined as NPI-C: Hallucinations domain score of ≥ 2 on 2 of the 7 items
- MMSE score of 8 to 22, inclusive, at Screening.
You may not qualify if:
- Psychotic symptoms that are primarily attributable to a condition other than the AD causing the dementia.
- History of major depressive episode with psychotic features during the 12 months prior to Screening.
- History of bipolar disorder, schizophrenia, or schizoaffective disorder.
- Significant or severe medical conditions including pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, cardiovascular, or oncologic disease or any other condition that, in the opinion of the Investigator, could jeopardize the safety of the subject, ability to complete or comply with the study procedures or validity of the study results.
- History or high risk of urinary retention, gastric retention, or narrow-angle glaucoma as evaluated by the Investigator.
- Prior exposure to KarXT.
- History of hypersensitivity to KarXT excipients or trospium chloride.
- Experienced any significant adverse events (AEs) due to trospium.
- Participation in another clinical study in which the subject received an experimental or investigational drug within 3 months before Screening or has participated in more than 2 clinical studies in the 12 months prior to Screening.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (154)
Local Institution - 1116
Chandler, Arizona, 85286, United States
Local Institution - 1044
Phoenix, Arizona, 85012-2836, United States
Local Institution - 1104
Anaheim, California, 92805-5854, United States
Local Institution - 1119
Canoga Park, California, 91303-1844, United States
Local Institution - 1151
Encino, California, 91316, United States
Local Institution - 1142
Lancaster, California, 93534-2839, United States
Local Institution - 1117
Los Alamitos, California, 90720-6506, United States
Local Institution - 1103
Sherman Oaks, California, 91403-2131, United States
Local Institution - 1007
Walnut Creek, California, 94596, United States
Local Institution - 1160
Apopka, Florida, 32703-5835, United States
Local Institution - 1156
Clermont, Florida, 34711-5190, United States
Local Institution - 1138
Cutler Bay, Florida, 33189-1230, United States
Local Institution - 1162
Delray Beach, Florida, 33445-2581, United States
Local Institution - 1164
Doral, Florida, 33122-1620, United States
Local Institution - 1165
Fort Myers, Florida, 33912-4302, United States
Local Institution - 1155
Hialeah, Florida, 33012-3158, United States
Local Institution - 1107
Hialeah, Florida, 33012-3618, United States
Local Institution - 1120
Hialeah, Florida, 33012-4648, United States
Local Institution - 1140
Hialeah, Florida, 33016-1814, United States
Local Institution - 0150
Homestead, Florida, 33032-8187, United States
Local Institution - 1145
Homestead, Florida, 33032-8187, United States
Local Institution - 1127
Largo, Florida, 33777-1359, United States
Local Institution - 1039
Maitland, Florida, 32751-5669, United States
Local Institution - 1146
Maitland, Florida, 32751-6138, United States
Local Institution - 1159
Miami, Florida, 33032, United States
Local Institution - 1118
Miami, Florida, 33122-1721, United States
Local Institution - 1111
Miami, Florida, 33126-5683, United States
Local Institution - 1108
Miami, Florida, 33133-4231, United States
Local Institution - 1125
Miami, Florida, 33135-1601, United States
Local Institution - 1115
Miami, Florida, 33135, United States
Local Institution - 1143
Miami, Florida, 33145-2455, United States
Local Institution - 1113
Miami, Florida, 33155-6630, United States
Local Institution - 1009
Miami, Florida, 33155, United States
Local Institution - 1129
Miami, Florida, 33165-3947, United States
Local Institution - 1150
Miami, Florida, 33165, United States
Local Institution - 1109
Miami, Florida, 33174-2950, United States
Local Institution - 1158
Miami, Florida, 33175, United States
Local Institution - 1147
Miami, Florida, 33176-7947, United States
Local Institution - 1105
Miami, Florida, 33179-2537, United States
Local Institution - 1157
Miami, Florida, 33184-1412, United States
Local Institution - 1126
Miami Gardens, Florida, 33056-4000, United States
Local Institution - 1102
Miami Lakes, Florida, 33014-6435, United States
Local Institution - 1136
Orlando, Florida, 32806-1041, United States
Local Institution - 1112
Orlando, Florida, 32807-3555, United States
Local Institution - 1137
Port Orange, Florida, 32127-2914, United States
Health Synergy Clinical Research,LLC - Stuart
Stuart, Florida, 34994, United States
Local Institution - 1133
Sweetwater, Florida, 33182, United States
Local Institution - 1041
Tampa, Florida, 33607-4629, United States
Local Institution - 1124
Tampa, Florida, 33614-2700, United States
Local Institution - 1123
Tampa, Florida, 33614-2846, United States
Local Institution - 1110
Tampa, Florida, 33629-5837, United States
Local Institution - 1040
The Villages, Florida, 32159-8986, United States
Local Institution - 1131
Viera, Florida, 32940, United States
Local Institution - 1152
Augusta, Georgia, 30912-0020, United States
Local Institution - 1141
Columbus, Georgia, 31909-1693, United States
Local Institution - 1161
Decatur, Georgia, 30030, United States
Local Institution - 1148
Elgin, Illinois, 60123-9215, United States
Local Institution - 1114
Marrero, Louisiana, 70072-3083, United States
Local Institution - 1139
Rochester Hills, Michigan, 48307-2760, United States
Local Institution - 1132
Flowood, Mississippi, 39232, United States
Local Institution - 1144
Las Vegas, Nevada, 89106-4145, United States
Local Institution - 1153
New Hyde Park, New York, 11042-2062, United States
Local Institution - 1135
Port Jefferson Station, New York, 11776-3386, United States
Local Institution - 1122
Dayton, Ohio, 45459-4248, United States
Local Institution - 1149
Malvern, Pennsylvania, 19355-3267, United States
Local Institution - 1106
Cypress, Texas, 77429-6070, United States
Local Institution - 1163
Houston, Texas, 77074-2085, United States
Local Institution - 1154
Katy, Texas, 77450-1759, United States
Local Institution - 1121
Red Oak, Texas, 75154, United States
Local Institution - 1134
Stafford, Texas, 77477-3929, United States
Local Institution - 2801
Hasselt, Limburg, 3500, Belgium
Local Institution - 2802
Leuven, Vlaams Brabant, 3000, Belgium
Local Institution - 2803
Roeselare, West-Vlaanderen, 8800, Belgium
Local Institution - 1605
Calgary, Alberta, T2N 1N4, Canada
Local Institution - 1603
Hamilton, Ontario, ON L8M 1W9, Canada
Local Institution - 1602
Toronto, Ontario, M5B 1W8, Canada
Local Institution - 1604
Whitby, Ontario, L1N 5S9, Canada
Local Institution - 1606
Montreal, Quebec, H4H 1R3, Canada
Local Institution - 1601
Verdun, Quebec, H4H 1R3, Canada
Local Institution - 6002
Providencia, Santiago Metropolitan, 7500000, Chile
Local Institution - 6003
Antofagasta, 127-0244, Chile
Local Institution - 6001
Las Condes, 7550000, Chile
Local Institution - 7007
Hefei, Anhui, 230022, China
Local Institution - 7004
Beijing, Beijing Municipality, 100025, China
Local Institution - 7005
Beijing, Beijing Municipality, 100088, China
Local Institution - 7015
Chongqing, Chongqing Municipality, 400016, China
Local Institution - 7008
Guangzhou, Guangdong, 0, China
Local Institution - 7016
Guangzhou, Guangdong, 510120, China
Local Institution - 7009
Guangzhou, Guangdong, 510260, China
Local Institution - 7003
Shenzhen, Guangdong, 518118, China
Local Institution - 7014
Nanjing, Jiangsu, 210009, China
Local Institution - 7013
Nanjing, Jiangsu, 210011, China
Local Institution - 7012
Nanchang, Jiangxi, 330008, China
Local Institution - 7001
Shanghai, Shanghai Municipality, 200030, China
Local Institution - 7011
Shanghai, Shanghai Municipality, 200080, China
Local Institution - 7002
Chengdu, Sichuan, 610000, China
Local Institution - 7019
Tianjin, Tianjin Municipality, 300222, China
Local Institution - 7017
Hangzhou, Zhejiang, 310003, China
Local Institution - 7010
Hangzhou, Zhejiang, 310013, China
Local Institution - 7006
Hangzhou, Zhejiang, 310014, China
Local Institution - 7020
Hangzhou, Zhejiang, 310016, China
Local Institution - 7018
Wenzhou, Zhejiang, 325000, China
Local Institution - 4805
Athens, Attica, 115 21, Greece
Local Institution - 4803
Athens, Attica, 115 26, Greece
Local Institution - 4802
Chaidari, Athens, Attica, 124 62, Greece
Local Institution - 4806
Marousi, Attica, 151 23, Greece
Local Institution - 4801
Heraklion, 71110, Greece
Local Institution - 4601
Pécs, Baranya, 7633, Hungary
Local Institution - 4602
Budapest, 1083, Hungary
Local Institution - 4603
Miskolc, 3526, Hungary
Local Institution - 1502
Saltillo Centro, Coahuila, 25000, Mexico
Local Institution - 1504
Zona Urbana Río Tijuana, Estado de Baja California, 22010, Mexico
Local Institution - 1507
Zapopan, Jalisco, 45170, Mexico
Local Institution - 1503
Monterrey, Nuevo León, 64460, Mexico
Local Institution - 1505
Monterrey, Nuevo León, 64620, Mexico
Local Institution - 1501
Culiacán, Sinaloa, 80020, Mexico
Local Institution - 1506
México, 03100, Mexico
Local Institution - 6102
Miraflores, Lima region, 15046, Peru
Local Institution - 6103
Pueblo Libre, Lima region, 15084, Peru
Local Institution - 6101
Callao, Callao 2, Peru
Local Institution - 4206
Lublin, Lublin Voivodeship, 20-064, Poland
Local Institution - 4207
Lodz, Lódzkie, 90-349, Poland
Local Institution - 4203
Sopot, Pomeranian Voivodeship, 81-855, Poland
Local Institution - 4208
Katowice, Silesian Voivodeship, 40-156, Poland
Local Institution - 4204
Bydgoszcz, 85-080, Poland
Local Institution - 4205
Katowice, 40-282, Poland
Local Institution - 4202
Lodz, 90-227, Poland
Local Institution - 4209
Siemianowice Śląskie, 41-100, Poland
Local Institution - 4201
Ścinawa, 59-330, Poland
Local Institution - 7208
Buk-gu, Daegu Gwang'yeogsi, 41404, South Korea
Local Institution - 7207
Seongnam-si, Gyeonggido, 13496, South Korea
Local Institution - 7205
Incheon, Incheon Gwang'yeogsi, 21565, South Korea
Local Institution - 7204
Busan, 49201, South Korea
Local Institution - 7202
Seongnam-si, 0, South Korea
Local Institution - 7206
Seoul, 03080, South Korea
Local Institution - 7203
Seoul, 07071, South Korea
Local Institution - 7201
Seoul, 143-729, South Korea
Local Institution - 2901
Geneva, Genève (fr), CH-1205, Switzerland
Local Institution - 2902
Lausanne, Vaud (fr), 1011, Switzerland
Local Institution - 4702
Atakum, Samsun, 55270, Turkey (Türkiye)
Local Institution - 4701
Eskişehir, 26040, Turkey (Türkiye)
Local Institution - 4704
Istanbul, 34093, Turkey (Türkiye)
Local Institution - 4705
Izmir, 35210, Turkey (Türkiye)
Local Institution - 4703
Izmir, 35575, Turkey (Türkiye)
Local Institution - 2110
Ilford, Greater London, IG1 4HP, United Kingdom
Local Institution - 2108
Swinton, Greater Manchester, M27 8FF, United Kingdom
Local Institution - 2101
London, Surrey, SE5 8AZ, United Kingdom
Local Institution - 2105
Aberdeen, AB25 2ZL, United Kingdom
Local Institution - 2109
Chertsey, KT16 9AU, United Kingdom
Local Institution - 2112
Edinburgh, EH4 2XU, United Kingdom
Local Institution - 2106
Leeds, LS7 3JX, United Kingdom
Local Institution - 2104
Motherwell, ML1 4UF, United Kingdom
Local Institution - 2111
Preston, PR2 9HT, United Kingdom
Local Institution - 2107
Sheffield, SouthYorkshire, s5 7JT, United Kingdom
Related Links
Study Officials
- STUDY DIRECTOR
Bristol-Myers Squibb
Bristol-Myers Squibb
Central Study Contacts
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
First line of the email MUST contain NCT # and Site #.
CONTACT
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 3, 2023
First Posted
November 13, 2023
Study Start
August 28, 2023
Primary Completion (Estimated)
December 9, 2026
Study Completion (Estimated)
December 9, 2026
Last Updated
April 30, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, CSR
- Time Frame
- See Plan Description
- Access Criteria
- See Plan Description
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html